Panke Qu

The Ohio State University — United States

Medicine · Health Sciences

22h-index2.1kcitations37works26.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(29), COVID-19 Clinical Research Studies(11), SARS-CoV-2 detection and testing(10), Animal Virus Infections Studies(7), Mosquito-borne diseases and control(5)

Publications37 total

Cellular signatures of hybrid immunity underpinning superior mucosal protection 2420
The Journal of Immunology·2025Open Access
Mechanisms of superior respiratory IgA responses against SARS-CoV-2 after mucosal vaccination 2158
The Journal of Immunology·2025Open Access
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective
Nature Communications·2024· 11 citedOpen Access
Respiratory mucosal immunity against SARS-CoV-2 after vaccination and infection
The Journal of Immunology·2024
Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination
Journal of Medical Virology·2024Open Access
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
Cell·2024· 149 citedOpen Access
Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
Emerging Microbes & Infections·2023· 84 citedOpen Access
A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern
Proceedings of the National Academy of Sciences·2023· 8 citedOpen Access
Continued evasion of neutralizing antibody response by Omicron XBB.1.16
Cell Reports·2023· 26 citedOpen Access
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
2023· 48 citedOpen Access
Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3
2023· 9 citedOpen Access
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
Cell Reports Medicine·2023· 29 citedOpen Access
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Cell Reports·2023· 183 citedOpen Access
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
2023· 49 citedOpen Access
Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
mBio·2023· 37 citedOpen Access
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Cell Host & Microbe·2022· 278 citedOpen Access
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
2022· 87 citedOpen Access
Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
2022· 8 citedOpen Access
Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
Cell Host & Microbe·2022· 121 citedOpen Access
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
New England Journal of Medicine·2022· 86 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Shan‐Lu Liu(29), Yi-Min Zheng(25), John P. Evans(24), Linda J. Saif(23), Eugene M. Oltz(23), Richard J. Gumina(21), Claire Carlin(20), Julia N. Faraone(18), Kai Xu(15), Gerard Lozanski(13), Cong Zeng(10), Rama K. Mallampalli(8), Joseph S. Bednash(7), Ashish R. Panchal(6), Daniel Jones(6), Mirela Anghelina(5), Patrick Stevens(5), Soledad Fernández(5), Peter J. Mohler(5), Daniel M. Jones(4)